Avadel Pharmaceuticals-adr (AVDL) Technical Analysis
$10.00▲0.5%
Market is closed - opens 8 PM, 09 Dec 2024
Insights
- Avadel Pharmaceuticals-adr is currently in a neutral trading position according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Avadel Pharmaceuticals-adr stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Avadel Pharmaceuticals-adr stock is in a downtrend↘️
- Based on analysis of the Pivot Points, the current market trend for Avadel Pharmaceuticals-adr stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 32.43 | Neutral |
Stochastic | 19.22, 17.52 | Buy |
Ultimate Oscillator | 39.19 | Neutral |
Stochastic Relative Strength Index | 11.94, 31.3 | Neutral |
Moving Average Convergence Divergence | -0.87, -0.72 | Neutral |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.94 | Sell |
20 | 11.86 | Sell |
50 | 12.79 | Sell |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.81 | Sell |
20 | 11.54 | Sell |
50 | 12.63 | Sell |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.86 | Sell |
20 | 12.01 | Sell |
50 | 12.83 | Sell |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 10.04 | Sell |
20 | 10.43 | Sell |
50 | 11.41 | Sell |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 9.98 | Buy |
20 | 9.96 | Sell |
50 | 10.88 | Sell |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 10.59 |
Resistance L2 | 10.39 |
Resistance L1 | 10.18 |
Pivot Point | 9.98 |
Support L1 | 9.77 |
Support L2 | 9.57 |
Support L3 | 9.36 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.